BMRI - Is This "Too Big to Fail" Giant a Must-Buy in 2026?
As of June 25, 2026, PT Bank Mandiri (Persero) Tbk (BMRI) presents a compelling case for investors looking for a mix of stability, income, and long-term growth. Currently trading at Rp3,970, the bank is the largest in Indonesia by assets (exceeding Rp2,000 trillion) and serves over 100 million customers through a network of more than 3,700 branches.
The Fundamental Strength: A Wide Moat Powerhouse
BMRI isn't just large; it’s strategically dominant. According to a fundamental analysis, the bank possesses a "Wide Moat" score of 44/50, driven by several key factors:
- Regulatory & Scale Advantage: As a BUMN (State-Owned Enterprise), BMRI is considered "too big to fail". Its status provides a regulatory barrier that is nearly impossible for new competitors to breach, requiring massive capital and years of licensing.
- Low-Cost Funding: BMRI excels at capturing low-cost funds. It boasts a CASA ratio of 80%+, meaning the vast majority of its funding comes from cheap savings and current accounts, keeping its cost of funds below 3%.
- High Profitability: For a bank of its scale, an ROE (Return on Equity) of 18.63% is exceptionally competitive. This efficiency translates into a net income exceeding Rp50 trillion annually.
- Dividend Appeal: For income-oriented investors, BMRI is a consistent performer, typically paying out 60-70% of its net income as dividends, resulting in an attractive yield of approximately 5%+.
Digital Transformation: The Livin! Engine
Beyond traditional lending, BMRI has successfully pivoted to digital banking. Its Livin! by Mandiri app has reached over 30 million Monthly Active Users (MAU). This super-app is a significant growth engine, with fee-based income from digital services growing at over 30% year-on-year. Currently, fee income accounts for roughly 35% of the bank's total revenue.
Technical Outlook: Finding the Bottom
While the fundamentals are rock-solid, the technical picture as of June 2026 reflects a broader bearish market regime. The stock is currently in a Wyckoff "Late Markdown" phase, meaning it has seen a significant decline from its 52-week high of Rp4,952.
- Support Levels: Strong support is identified at the 52-week low of Rp3,610.
- Valuation: At a PER of 6.51x and a PBV of 1.21x, the stock is considered significantly undervalued compared to its historical norms and fair value.
- Momentum: Indicators like the RSI (41.5) and MACD show that while the trend is still bearish, the selling pressure is beginning to slow down.
Investment Thesis and Strategy
The overall verdict for BMRI is a BUY. The long-term investment thesis relies on the bank's role as a proxy for the Indonesian economy and its ability to maintain high margins through its digital and corporate lending engines.Price Targets:
- 12-Month Target: Rp5,200 – Rp5,800 (representing a potential upside of 31-46%).
- Fair Value: Estimated between Rp4,800 and Rp5,200 based on residual income models.
Entry Strategies:
- Aggressive: Buy 50% at current levels, and the remaining 50% if the price pulls back to the Rp3,600-Rp3,700 range.
- Conservative: Use a Dollar Cost Averaging (DCA) approach over the next two months to mitigate short-term volatility.
- Income Play: Simply buy and hold for the 5%+ dividend yield, treating any capital appreciation as a bonus.
Risks to Watch
While the "too big to fail" status provides a safety net, investors should remain aware of NPL (Non-Performing Loan) risks if the economy slows down, as well as potential political pressure regarding government-mandated lending programs
Disclaimer: This analysis is for educational purposes and academic exercise only. It does not constitute investment advice. Always perform your own due diligence.